Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine
Objective This study aims to characterize the adverse events (AEs) following the administration of the mRNA-1273 COVID-19 vaccine from the Vaccine Adverse Event Reporting System (VAERS) data. Methods In this case/non-case analysis, reports between 1 January 2021, and 27 October 2022, were extracted...
Main Authors: | Angel Shabu, Prasad S. Nishtala |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Expert Review of Vaccines |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14760584.2023.2260477 |
Similar Items
-
Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review
by: Angel Shabu, et al.
Published: (2023-12-01) -
Myasthenia Gravis Presenting after Administration of the mRNA-1273 Vaccine
by: Yoji Hoshina, et al.
Published: (2022-07-01) -
Association Between Fever and Antibody Titer Trends After a Third Dose of the mRNA-1273 Vaccine
by: Naomi Matsumoto, et al.
Published: (2022-12-01) -
Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
by: Suresh Babu Chellapandian, et al.
Published: (2022-04-01) -
Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters
by: Bethany Girard, et al.
Published: (2024-03-01)